Funding is a crucial point to guarantee access to the gene and cell therapies market and thus the availability of French patients. However, the major innovation they represent requires an in-depth review of our health system. Indeed, the added value of these therapies is the prospect of treating illnesses that were previously incurable in a single administration. However, their development entails very high costs with which it will be necessary to deal in particular to ensure the sustainability of their coverage by health insurance.